Compare PRTC & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRTC | BETR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | 90 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.2M | 538.7M |
| IPO Year | N/A | N/A |
| Metric | PRTC | BETR |
|---|---|---|
| Price | $18.25 | $38.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 3.3K | ★ 517.9K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $54.06 |
| Revenue Next Year | N/A | $66.68 |
| P/E Ratio | $8.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.50 | $10.81 |
| 52 Week High | $19.92 | $94.06 |
| Indicator | PRTC | BETR |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 55.60 |
| Support Level | $18.07 | $26.89 |
| Resistance Level | $19.49 | $41.23 |
| Average True Range (ATR) | 0.49 | 3.54 |
| MACD | 0.39 | 0.09 |
| Stochastic Oscillator | 95.67 | 49.90 |
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.